Tumor-Associated Mast Cells in Thyroid Cancer

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Visciano, Carla ^a,b   Prevete, Nella ^a   Liotti, Federica ^a,b   Marone, Gianni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE A; CHYMASE; CXCL1 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; INTERLEUKIN 13; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 8; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROTEOGLYCAN; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D;

CANCER GROWTH; CARCINOGENESIS; CELL INTERACTION; CELL POPULATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNE RESPONSE; MAST CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; THYROID CANCER; TUMOR MICROENVIRONMENT;

EID: 84941075783     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/705169     Document Type: Review

References (73)

1. T. Carling and R. Udelsman, "Thyroid cancer, " Annual Review of Medicine, vol. 65, pp. 125-137, 2014.
2. P. M. Sadow and W. C. Faquin, "Poorly differentiated thyroid carcinoma: an incubating entity, " Frontiers in Endocrinology, vol. 3, article 77, 2012.
3. M. Ragazzi, A. Ciarrocchi, V. Sancisi, G. Gandolfi, A. Bisagni, and S. Piana, "Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer, " International Journal of Endocrinology, vol. 2014, Article ID790834, 13 pages, 2014.
4. J. J. Gruber and A. Dimitrios Colevas, "Differentiated thyroid cancer: focus on emerging treatments for radioactive iodinerefractory patients, " Oncologist, vol. 20, no. 2, pp. 113-126, 2015.
5. E. Elinav, R. Nowarski, C. A. Thaiss, B. Hu, C. Jin, and R. A. Flavell, "Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms, " Nature Reviews Cancer, vol. 13, no. 11, pp. 759-771, 2013.
6. M. R. Galdiero, E. Bonavita, I. Barajon, C. Garlanda, A. Mantovani, and S. Jaillon, "Tumor associated macrophages and neutrophils in cancer, " Immunobiology, vol. 218, no. 11, pp. 1402-1410, 2013.
7. A. Del Prete, P. Allavena, G. Santoro, R. Fumarulo, M. M. Corsi, and A. Mantovani, "Molecular pathways in cancer-related inflammation, " Biochemia Medica, vol. 21, no. 3, pp. 264-275, 2011.
8. R. M. Melillo, M. D. Castellone, V. Guarino et al., "The RET/ PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells, " Journal of Clinical Investigation, vol. 115, no. 4, pp. 1068-1081, 2005.
9. F. Liotti, C. Visciano, and R. M. Melillo, "Inflammation in thyroid oncogenesis, " American Journal of Cancer Research, vol. 2, no. 3, pp. 286-297, 2012.
10. A. Antonelli, S. M. Ferrari, P. Fallahi et al., "Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer, " Cytokine, vol. 59, no. 2, pp. 218-222, 2012.
11. A. Antonelli, S. M. Ferrari, P. Fallahi et al., "Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists, " Endocrine-Related Cancer, vol. 16, no. 4, pp. 1299-1311, 2009.
12. M. Rotondi, F. Coperchini, P. Pignatti et al., "Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation?" Journal of Clinical Endocrinology andMetabolism, vol. 98, no. 1, pp. 308-313, 2013.
13. G. Stassi, M. Todaro, M. Zerilli et al., "Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10, " Cancer Research, vol. 63, no. 20, pp. 6784-6790, 2003.
14. L. L. Cunha, M. A. Marcello, and L. S. Ward, "The role of the inflammatory microenvironment in thyroid carcinogenesis, " Endocrine-Related Cancer, vol. 21, no. 3, pp. R85-R103, 2014.
15. F. Gogali, G. Paterakis, G. Z. Rassidakis et al., "Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid, " The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 5, pp. 1474-1482, 2012.
16. F. Gogali, G. Paterakis, G. Z. Rassidakis, C. I. Liakou, and C. Liapi, "CD3-CD16-CD56bright immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer, " Thyroid, vol. 23, no. 12, pp. 1561-1568, 2013.
17. C. Ugolini, F. Basolo, A. Proietti et al., "Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma, " Thyroid, vol. 17, no. 5, pp. 389-393, 2007.
18. A. Proietti, C.Ugolini, R.M.Melillo et al., "Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters, " Thyroid, vol. 21, no. 11, pp. 1209-1215, 2011.
19. B. Caillou, M. Talbot, U. Weyemi et al., "Tumor-Associated macrophages (TAMs) forman interconnected cellular supportive network in anaplastic thyroid carcinoma, " PLoS ONE, vol. 6, no. 7, Article ID e22567, 2011.
20. M. Ryder, M. Gild, T. M. Hohl et al., "Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression, " PLoS ONE, vol. 8, no. 1, Article ID e54302, 2013.
21. F.Borriello, F. Granata, G. Varricchi, A. Genovese, M.Triggiani, and G.Marone, "Immunopharmacological modulation of mast cells, " Current Opinion in Pharmacology, vol. 17, no. 1, pp. 45-57, 2014.
22. T.Marichal, M. Tsai, and S. J. Galli, "Mast cells: potential positive and negative roles in tumor biology, " Cancer Immunology Research, vol. 1, no. 5, pp. 269-279, 2013.
23. G. Marone, G. Varricchi, S. Loffredo et al., "Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis, " European Journal of Pharmacology, 2015.
24. A.Detoraki, R. I. Staiano, F.Granata et al., "Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects, " Journal of Allergy and Clinical Immunology, vol. 123, no. 5, pp. 1142-e5, 2009.
25. P. Pittoni, C. Tripodo, S. Piconese et al., "Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers, " Cancer Research, vol. 71, no. 18, pp. 5987-5997, 2011.
26. R. M. Melillo, V. Guarino, E. Avilla et al., "Mast cells have a protumorigenic role in human thyroid cancer, " Oncogene, vol. 29, no. 47, pp. 6203-6215, 2010.
27. C. Marinaccio, B. Nico, E. Maiorano, G. Specchia, and D. Ribatti, "Insights in hodgkin lymphoma angiogenesis, " Leukemia Research, vol. 38, no. 8, pp. 857-861, 2014.
28. D. Ribatti, B. Nico, G. Ranieri, G. Specchia, and A. Vacca, "The role of angiogenesis in human non-Hodgkin lymphomas, " Neoplasia, vol. 15, no. 3, pp. 231-238, 2013.
29. A. Rabenhorst, M. Schlaak, L. C. Heukamp et al., "Mast cells play a protumorigenic role in primary cutaneous lymphoma, " Blood, vol. 120, no. 10, pp. 2042-2054, 2012.
30. Y.Ma, R. F. Hwang, C. D. Logsdon, and S. E.Ullrich, "Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer, " Cancer Research, vol. 73, no. 13, pp. 3927-3937, 2013.
31. P. Pittoni and M. P. Colombo, "The dark side of mast celltargeted therapy in prostate cancer, " Cancer Research, vol. 72, no. 4, pp. 831-835, 2012.
32. M. J. Strouch, E. C. Cheon, M. R. Salabat et al., "Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression, " Clinical Cancer Research, vol. 16, no. 8, pp. 2257-2265, 2010.
33. G. Marone and F. Granata, "Angiogenesis, lymphangiogenesis and clinical implications, " Chemical Immunology and Allergy, vol. 99, pp. 15-36, 2014.
34. N. Prevete, R. I. Staiano, F. Granata et al., "Expression and function of angiopoietins and their tie receptors in human basophils and mast cells, " Journal of Biological Regulators & Homeostatic Agents, vol. 27, no. 3, pp. 827-839, 2013.
35. S. Loffredo, R. I. Staiano, F. Granata, A. Genovese, and G. Marone, "Immune cells as a source and target of angiogenic and lymphangiogenic factors, " Chemical Immunology and Allergy, vol. 99, pp. 15-36, 2014.
36. H.-J. Jeong, H.-A. Oh, S.-Y. Namet al., "The critical role of mast cell-derived hypoxia-inducible factor-1α in human and mice melanoma growth, " International Journal of Cancer, vol. 132, no. 11, pp. 2492-2501, 2013.
37. M. J. Carlini, M. C. L. Dalurzo, J. M. Lastiri et al., "Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance, " Human Pathology, vol. 41, no. 5, pp. 697-705, 2010.
38. M. A. Zaidi and A. K. Mallick, "A study on assessment of mast cells in oral squamous cell carcinoma, " Annals of Medical and Health Sciences Research, vol. 4, no. 3, pp. 457-460, 2014.
39. T. T. Maciel, I. C. Moura, and O. Hermine, "The role of mast cells in cancers, " F1000Prime Reports, vol. 7, articleA9, 2015.
40. E. Gounaris, S. E. Erdman, C. Restaino et al., "Mast cells are an essential hematopoietic component for polyp development, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 50, pp. 19977-19982, 2007.
41. L. Soucek, E. R. Lawlor, D. Soto, K. Shchors, L. B. Swigart, and G. I. Evan, "Mast cells are required for angiogenesis andmacroscopic expansion of Myc-induced pancreatic islet tumors, " Nature Medicine, vol. 13, no. 10, pp. 1211-1218, 2007.
42. S.-Y. Tan, Y. Fan, H.-S. Luo, Z.-X. Shen, Y. Guo, and L.-J. Zhao, "Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer, " World Journal of Gastroenterology, vol. 11, no. 8, pp. 1210-1214, 2005.
43. R.-M. Amini, K. Aaltonen, H. Nevanlinna et al., "Mast cells and eosinophils in invasive breast carcinoma, " BMC Cancer, vol. 7, article 165, 2007.
44. C. Visciano, F. Liotti, N. Prevete et al., "Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-SLUG pathway, " Oncogene, 2015.
45. R. Kalluri and R. A. Weinberg, "The basics of epithelialmesenchymal transition, " The Journal of Clinical Investigation, vol. 119, no. 6, pp. 1420-1428, 2009.
46. M. A. Nieto, "Epithelial plasticity: a common theme in embryonic and cancer cells, " Science, vol. 342, no. 6159, Article ID 1234850, 2013.
47. J. P. Medema, "Cancer stem cells: the challenges ahead, " Nature Cell Biology, vol. 15, no. 4, pp. 338-344, 2013.
48. M. Todaro, F. Iovino, V. Eterno et al., "Tumorigenic and metastatic activity of human thyroid cancer stem cells, " Cancer Research, vol. 70, no. 21, pp. 8874-8885, 2010.
49. M. Shimamura, Y. Nagayama, M.Matsuse, S. Yamashita, and N. Mitsutake, "Analysis of multiple markers for cancer stem-like cells in human thyroid carcinoma cell lines, " Endocrine Journal, vol. 61, no. 5, pp. 481-490, 2014.
50. C.W. Jung, K. H. Han, H. Seol et al., "Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma, " International Journal of Clinical and Experimental Pathology, vol. 8, no. 1, pp. 560-568, 2015.
51. D. F. Quail and J. A. Joyce, "Microenvironmental regulation of tumor progression andmetastasis, " Nature Medicine, vol. 19, no. 11, pp. 1423-1437, 2013.
52. R. G. Hardy, C. Vicente-Dueñas, I. Gonzâlez-Herrero et al., "Snail family transcription factors are implicated in thyroid carcinogenesis, " American Journal of Pathology, vol. 171, no. 3, pp. 1037-1046, 2007.
53. K. Banovac, L. Ghandur-Mnaymneh, J. Leone, D. Neylan, and A. Rabinovitch, "Intrathyroidal mast cells express major histocompatibility complex class-II antigens, " International Archives of Allergy and Applied Immunology, vol. 90, no. 1, pp. 43-46, 1989.
54. K. Banovac and R. De Forteza, "The effect of mast cell chymase on extracellular matrix: studies in autoimmune thyroiditis and in cultured thyroid cells, " International Archives of Allergy and Immunology, vol. 99, no. 1, pp. 141-149, 1992.
55. D. Buehler, H. Hardin, W. Shan et al., "Expression of epithelialmesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas, " Modern Pathology, vol. 26, no. 1, pp. 54-61, 2013.
56. N.Wang, C.-R.Dong, R. Jiang et al., "Overexpression ofHIF-1α, metallothionein and SLUG is associated with high TNM stage and lymph node metastasis in papillary thyroid carcinoma, " International Journal of Clinical and Experimental Pathology, vol. 7, no. 1, pp. 322-330, 2013.
57. J. García-Quiroz and J. Camacho, "Astemizole: an old antihistamine as a new promising anti-cancer drug, " Anti-Cancer Agents in Medicinal Chemistry, vol. 11, no. 3, pp. 307-314, 2011.
58. B. Blaya, F. Nicolau-Galmés, S. M. Jangi et al., "Histamine and histamine receptor antagonists in cancer biology, " Inflammation &Allergy-Drug Targets, vol. 9, no. 3, pp. 146-157, 2010.
59. P. Dhawan and A. Richmond, "Role of CXCL1 in tumorigenesis of melanoma, " Journal of Leukocyte Biology, vol. 72, no. 1, pp. 9-18, 2002.
60. S. Acharyya, T. Oskarsson, S. Vanharanta et al., "A CXCL1 paracrine network links cancer chemoresistance and metastasis, " Cell, vol. 150, no. 1, pp. 165-178, 2012.
61. M. Liu, S. Guo, and J. K. Stiles, "The emerging role of CXCL10 in cancer, " Oncology Letters, vol. 2, no. 4, pp. 583-589, 2011.
62. C. Palena, D. H. Hamilton, and R. I. Fernando, "Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment, " Future Oncology, vol. 8, no. 6, pp. 713-722, 2012.
63. D. J. J. Waugh and C. Wilson, "The interleukin-8 pathway in cancer, " Clinical Cancer Research, vol. 14, no. 21, pp. 6735-6741, 2008.
64. L. M. Campbell, P. J. Maxwell, and D. J. J. Waugh, "Rationale and means to target pro-inflammatory interleukin-8 (CXCL8) signaling in cancer, " Pharmaceuticals, vol. 6, no. 8, pp. 929-959, 2013.
65. S. Broutin, N. Ameur, L. Lacroix et al., "Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models, " Clinical Cancer Research, vol. 17, no. 7, pp. 2044-2054, 2011.
66. M. F. Sanmamed, O. Carranza-Rua, C. Alfaro et al., "Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins, " Clinical Cancer Research, vol. 20, no. 22, pp. 5697-5707, 2014.
67. J. K. Singh, B. M. Simões, S. J. Howell, G. Farnie, and R. B. Clarke, "Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells, " Breast Cancer Research, vol. 15, no. 4, article 210, 2013.
68. C. Ginestier, S. Liu, M. E. Diebel et al., "CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts, "The Journal of Clinical Investigation, vol. 120, no. 2, pp. 485-497, 2010.
69. C.-J. Chang, Y. Chien, K.-H. Lu et al., "Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells, " Biochemical and Biophysical Research Communications, vol. 415, no. 2, pp. 245-251, 2011.
70. T.C.Moon, A. DeanBefus, andM.Kulka, "Mast cell mediators: their differential release and the secretory pathways involved, " Frontiers in Immunology, vol. 5, article 569, 2014.
71. S. J.Galli, J.Kalesnikoff, M. A. Grimbaldeston, A.M. Piliponsky, C. M. M.Williams, and M. Tsai, "Mast cells as 'tunable' effector and immunoregulatory cells: recent advances, " Annual Review of Immunology, vol. 23, pp. 749-786, 2005.
72. W. Fang, L. Ye, L. Shen et al., "Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8, " Carcinogenesis, vol. 35, no. 8, 2014.
73. W. Qing, W.-Y. Fang, L. Ye et al., "Density of tumor-associated macrophages correlateswith lymph node metastasis in papillary thyroid carcinoma, " Thyroid, vol. 22, no. 9, pp. 905-910, 2012.